Independent research-data planningEditorial and review policy
PHPeptide HarborResearch Data Harbor
Menu ▼
Peptide Harbor / Lab Notes

Conjugation dossier

What changes when CJC-1295 includes the DAC albumin-binding group?

A molecule-specific dossier for the maleimido-modified hGRF(1-29) analogue, its formula and mass, and evidence needed to distinguish the DAC entity.

Reviewed by Peptide Harbor editorial reviewUpdated 2026-08-03Educational research-data guidance

Answer first

CJC-1295 with DAC is not adequately described as a modified GRF sequence alone. The reviewed compound includes a maleimido-derived group placed on the peptide so it can form an albumin bioconjugate; that group changes the expected molecular entity, formula, mass, and identity evidence plan.

Reviewed Chemical LedgerCJC-1295 with DAC
Molecular form representedMaleimido-modified hGRF(1-29) analogue represented by PubChem CID 91971820
CAS number
446262-90-4
Molecular formula
C165H269N47O46
Average molecular weight
3647.2 g/mol average molecular weight
Exact mass
3646.0188391 Da
Reviewed peptide designationTetrasubstituted hGRF(1-29) analogue with a C-terminal maleimidopropionamide-derived lysine
Structural notes
  • Four hGRF(1-29) backbone substitutions described in the development record
  • N-epsilon-3-maleimidopropionamide derivative of lysine at the C terminus
Known Aliases / Code Names:CJC-1295CJC 1295CJC-1295 DACUNII-62RC32V9N7

Field-level sources

PubChem CID 91971820: CJC-1295

National Library of Medicine / PubChem · accessed 2026-08-03

Supports: name, molecularForm, cas, formula, weight, exactMass, aliases

Identification of CJC-1295 as a long-lasting hGRF analogue

Endocrinology / PubMed · accessed 2026-08-03

Supports: peptideDesignation, modifications

Where this framework helps

  • Distinguishing DAC-modified material from no-DAC naming
  • Defining an expected form before intact-mass comparison
  • Planning evidence around a reactive maleimido-derived group

Limits to keep visible

  • The compound record does not describe an albumin-conjugated project sample by itself.
  • No-DAC or Modified GRF(1-29) data must not be copied into this ledger.
  • This dossier excludes use instructions, pharmacologic promises, and sales content.
01

Include the DAC group in the identity statement

The original CJC-1295 paper describes a tetrasubstituted hGRF(1-29) analogue carrying an N-epsilon-3-maleimidopropionamide lysine derivative. The expected molecular form must therefore include more than the peptide backbone.

02

Define the sample state before measuring mass

A free reactive peptide, hydrolyzed material, and an albumin conjugate are not the same mass target. The packet should state which state the method is designed to observe.

03

Keep nomenclature under review

Common market labels often shorten both forms to CJC-1295. A defensible record includes the compound identifier, DAC statement, formula, mass, and reference rather than relying on shorthand.

Primary and official sources

References used for this page

Visible FAQ

Questions research teams ask

What does DAC change in the record?

It adds a defined reactive modification to the peptide entity. That affects naming, formula, expected mass, and how free versus conjugated material is interpreted.

Can a no-DAC sequence report confirm CJC-1295 with DAC?

No. It may address part of the backbone, but it does not establish the DAC modification or the molecular state represented by the reported mass.

Does this page claim albumin conjugation occurred in a sample?

No. It explains the defined molecular design. A sample conclusion requires an appropriate experiment and actual data.